Category: Oncology & Colorectal Surgery
Locally advanced rectal cancer: how MDT neoadjuvant therapy can aim for remission and sphincter preservation
ไทย · English
· ☕ Buy me a coffee
Good outcomes in locally advanced rectal cancer often rely on neoadjuvant chemoradiotherapy or
total neoadjuvant therapy (TNT)
to shrink the tumor and nodal disease, then surgery (often with a temporary diverting stoma to protect a low anastomosis).
When healing is confirmed, stoma reversal may restore natural defecation in selected patients.
Surveillance uses
CEA
plus imaging/endoscopy — individual results depend on stage and the treating MDT.
Red flags — seek care now
- High fever, severe abdominal pain, rigid abdomen — possible anastomotic leak or peritonitis
- Heavy rectal or stoma bleeding, fainting, or collapse
- No stoma output with vomiting — possible obstruction
- Sudden chest pain, severe shortness of breath, or rapid new neurologic symptoms
1. Why rectal cancer needs an MDT (radiation, medical oncology, colorectal surgery)
The pelvis is a narrow space. Operating on a large tumor near the sphincter risks incomplete margins or a permanent stoma.
A multidisciplinary team sequences neoadjuvant therapy, surgery, and surveillance per
NCI rectal cancer treatment guidance.
2. Neoadjuvant therapy: shrinking the tumor before surgery
Neoadjuvant CRT and, in some protocols,
TNT
can markedly downsize tumors; some patients achieve pathologic complete response.
That improves chances of sphincter-preserving surgery (e.g., LAR) when anatomy allows — it is not a promise of cure without follow-up, and some patients still need APR.
Optional digestive-symptom check-in
Get a personalized severity summary from our Advisory team
Free GERD Severity Score assessment
This tool does not diagnose cancer. Rectal bleeding, unexplained weight loss, or suspected cancer need urgent medical evaluation.
3. Temporary stoma: protecting the anastomosis toward reversal
After low anastomosis, a diverting temporary stoma reduces
anastomotic leak
risk. Reversal is timed after healing checks — weeks to months. Not everyone is reversed; early bowel urgency or incomplete continence (LARS) can occur and needs follow-up.
Multidisciplinary treatment roadmap
| Phase | Team | Methods & goals | Impact on tumor / body |
|---|---|---|---|
| Staging / MDT | Colorectal surgery, radiation & medical oncology, radiology | MRI/CT, colonoscopy, biopsy, CEA | Choose neoadjuvant vs upfront surgery |
| Neoadjuvant CRT / TNT | Radiation + medical oncology | Protocol radiation + chemotherapy | Downsize tumor/nodes; possible pCR |
| Surgery ± temporary stoma | Colorectal surgeon | TME / LAR or APR | Clear margins; diverting stoma if needed |
| Reversal + surveillance | Surgery + medical oncology | Close stoma when ready; CEA + imaging | Restore natural route when possible; monitor remission |
Temporary stoma care vs reversal readiness
| Issue | While stoma is in place | Readiness for reversal |
|---|---|---|
| Anastomosis | Stool diverted; anastomosis rests | Healing confirmed (e.g., contrast study as ordered) |
| Wound / nutrition | Peristomal skin care; infection watch | Adequate nutrition; fit for anesthesia |
| Oncology timing | May overlap adjuvant therapy | Reversal timed with the center’s plan |
4. CEA surveillance and living in remission
A falling, stable CEA supports remission when paired with scheduled CT/MRI and colonoscopy.
Lab cutoffs vary (often <5 ng/mL in never-smokers — confirm your lab’s range).
Keep follow-up appointments; report new bleeding, obstruction symptoms, or rising CEA promptly.
Care comparison table
| Approach | Details | Goal | Safety notes |
|---|---|---|---|
| Neoadjuvant CRT / TNT | Radiation + chemo before surgery | Downstage; improve margins / sphincter odds | Marrow and bowel toxicity — team monitoring |
| Sphincter-preserving surgery | LAR when anatomy allows | Avoid permanent stoma when safe | Not for every patient; APR still needed for some |
| Temporary stoma ± reversal | Divert then close when ready | Reduce anastomotic leak | Reversal and baseline function not guaranteed |
| CEA + imaging | Blood markers + CT/endoscopy | Catch recurrence early | Interpret with clinical context |
Scientific mechanism (short)
By Asst. Prof. Dr. Norawit Raatpiboon:
Neoadjuvant therapy reduces pelvic tumor burden so total mesorectal excision can achieve clear margins more often and, when distance allows, preserve the sphincter.
A diverting stoma lowers pressure and stool load across a fragile anastomosis.
CEA tracks residual disease activity as one surveillance tool — never alone.
FAQ
Why chemotherapy and radiation before rectal cancer surgery?
To shrink disease, improve margins, and improve sphincter-preservation odds in selected locally advanced cases.
What decides sphincter-preserving surgery?
Distance from the anal verge, downstaged size, sphincter involvement, and safe anastomosis feasibility.
Why a temporary stoma, and when can it be reversed?
To protect the anastomosis; reverse after healing is confirmed — not everyone qualifies.
How does CEA relate to remission?
Falling, stable CEA plus imaging/endoscopy supports remission; CEA alone is not diagnostic.
Is TNT the same as older neoadjuvant CRT?
TNT intensifies systemic therapy before surgery under protocol rules; details vary by center.
What follow-up after stoma reversal?
Bowel function, CEA, imaging/endoscopy per plan; seek care for fever, severe pain, or heavy bleeding.
Support this writing
If this roadmap reduced fear around temporary stomas and neoadjuvant therapy, a coffee-sized donation keeps free, cited explainers online in Thai and English.
Citations (E-E-A-T)
Author: Asst. Prof. Dr. Norawit Raatpiboon · Consult colorectal surgery, radiation oncology, and medical oncology.
Medical disclaimer
Educational Oncology & Colorectal Surgery content for GEO/YMYL literacy — not individualized diagnosis or a treatment plan.
Sphincter preservation, stoma use/reversal, and CEA interpretation belong to your treating MDT.
For surgical emergencies, contact your team or an emergency department immediately.